Non-Identical Blood Type Transfusions for Patient Outcomes
(UD Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing whether giving patients blood that exactly matches their own type can reduce complications and deaths. It focuses on patients who need transfusions and are at higher risk of problems when given non-matching blood. The goal is to prevent harmful immune reactions by using matching blood types.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications.
Is it safe to receive a blood transfusion with a non-identical blood type?
Blood transfusions, including those with red blood cells, can have risks such as adverse reactions and complications. Studies have shown that factors like storage duration and irradiation can increase these risks, and transfusions can lead to serious reactions like hemolysis (destruction of red blood cells). While transfusions are common, they are associated with various adverse effects, especially in specific populations like newborns and patients with heart conditions.12345
How is the treatment of non-identical blood type transfusions unique compared to other treatments?
Non-identical blood type transfusions are unique because they involve transfusing blood that doesn't match the recipient's blood type exactly, which is not standard practice. This approach may focus on matching other blood components or antigens to improve outcomes, unlike traditional transfusions that prioritize exact blood type matching.678910
What data supports the effectiveness of the treatment Non-Identical Blood Type Transfusions for Patient Outcomes?
Research shows that red blood cell (RBC) transfusion therapy has been effective in reducing mortality and morbidity in patients with cancer who receive multiple transfusions. This suggests that RBC transfusions, even with non-identical blood types, could potentially improve patient outcomes.610111213
Who Is on the Research Team?
Donald Arnold
Principal Investigator
McMaster University
Are You a Good Fit for This Trial?
This trial is for adults over 18 with Myelodysplastic Syndrome (MDS) who don't have leukemia. They must need regular blood transfusions every 6 weeks or less, be stable according to their doctor's assessment, and not require special blood products due to reactions. People with blood group O or those unable to consent are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Transfusion Episode 1
Participants receive an ABO identical product during the first transfusion episode
Transfusion Episode 2
Participants receive an ABO non-identical product during the second transfusion episode
Follow-up
Participants are monitored for changes in biomarkers of inflammation and other safety parameters after transfusion
What Are the Treatments Tested in This Trial?
Interventions
- RBC transfusion
RBC transfusion is already approved in European Union, United States, Canada for the following indications:
- Anemia
- Blood loss
- Surgical procedures
- Anemia
- Blood loss
- Surgical procedures
- Trauma
- Anemia
- Blood loss
- Surgical procedures
Find a Clinic Near You
Who Is Running the Clinical Trial?
McMaster University
Lead Sponsor
CBS
Collaborator